KNKenichi Nakamura

Kenichi Nakamura

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kenichi Nakamura has a total of 17 co-authors. Here are the top co-authors by number of shared publications:

  • Hiroshi Hatada

    Faculty of Medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Miyazaki, Miyazaki, Japan

    2 shared publications
  • Hiroshi Kawakami

    Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan

    2 shared publications
  • Hisayoshi Iwakiri

    Faculty of Medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Miyazaki, Miyazaki, Japan

    2 shared publications
  • Keisuke Uchida

    Faculty of Medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Miyazaki, Miyazaki, Japan

    2 shared publications
  • Kenji Nagata

    Faculty of Medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Miyazaki, Miyazaki, Japan

    2 shared publications
  • Naomi Uchiyama

    Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki 889-1692, Japan

    2 shared publications

Latest Publications

  • Open Access

    An autopsy case of an adult woman with Rapid-Onset Obesity with Hypoventilation, Hypothalamic, Autonomic Dysregulation, and Neuroendocrine Tumors (ROHHAD(NET)) syndrome developing nonalcoholic steatohepatitis and hepatocellular carcinoma: A case report

    by Satoru Hasuike, Yoshinori Ozono, Keisuke Uchida, Souichiro Ogawa, Hotaka Tamura, Naomi Uchiyama, Hiroshi Hatada, Yuri Komaki, Kenichi Nakamura, Hisayoshi Iwakiri, et al.

    Background: Nonalcoholic steatohepatitis (NASH) is an important etiology of hepatocellular carcinoma (HCC), and there is no established therapy for this syndrome. Rapid-onset obesity with hypothalamic dysfunction, hypoventilation, autonomic dysregulation, and neural crest tumor (ROHHAD(NET)) is an extremely rare syndrome considered to be life-threatening, with death occurring around 10 years of age. We present the oldest known autopsy case of this syndrome that developed HCC. This case provided important information on not only improving the course of this syndrome, but also understanding the natural history and therapeutic modalities of NASH and HCC. Methods: The patient was diagnosed with ROHHAD(NET) syndrome in childhood, and liver cirrhosis due to NASH was diagnosed at age 17. HCC was detected at age 20, and embolization and irradiation were performed. At age 21, she died from accidental acute pancreatitis and subsequent liver failure and pulmonary hemorrhage. Results: Rapid onset of obesity, hypoventilation, and hypothalamic disturbance appeared in childhood and was diagnosed as this syndrome. At age 17, liver cirrhosis due to NASH was diagnosed by liver biopsy, and at age 20, HCC was diagnosed by imaging. Transarterial chemoembolization and irradiation were performed, and the HCC was well controlled for a year. Conclusion: At age 21, she died from accidental acute pancreatitis, subsequent liver failure and pulmonary hemorrhage. Autopsy revealed that the HCC was mostly necrotized. This case was valuable not only for other ROHHAD(NET) syndrome cases, but also in improving our understanding of the natural history of NASH and HCC.

  • Open Access

    Liver abscess in advanced hepatocellular carcinoma after atezolizumab plus bevacizumab treatment: A case report

    by Keisuke Uchida, Yoshinori Ozono, Naomi Uchiyama, Hiroshi Hatada, Kenichi Nakamura, Yuri Komaki, Hisayoshi Iwakiri, Satoru Hasuike, Kenji Nagata, Yuichiro Sato, et al.

    Rationale: Hepatocellular carcinoma (HCC) is the sixth most common type of cancer globally. Since 2020, combination treatment with atezolizumab and bevacizumab were approved in patients with unresectable HCC in Japan, and atezolizumab plus bevacizumab is the first-line treatment for unresectable HCC. Patient concerns: A 73-year-old Japanese man diagnosed with a large HCC was treated with atezolizumab plus bevacizumab. After 2 cycles, he had fever and fatigue and was admitted to the hospital. Diagnosis: Abdominal contrast-enhanced computed tomography revealed tumor necrosis in HCC with gas formation in the necrotic area. Laboratory examination revealed a white blood cell (WBC) count of 16,340/μL and C-reactive protein (CRP) level of 33.0 mg/dL. Based on the above findings, he was diagnosed with a liver abscess. Interventions: Percutaneous transhepatic liver abscess drainage and broad-spectrum antibiotics treatment were performed. Outcomes: Despite liver abscess drainage, persistent fever and no improvement in the WBC count or CRP level was observed. The patient’s respiratory condition and renal function gradually worsened; The patient’s general condition did not improve despite the ventilator support and continuous hemodiafiltration, and he died on day 37. Lessons: We report the first case of liver abscess after atezolizumab plus bevacizumab treatment for unresectable HCC.